Nunzia Pharmaceutical Company (NUNZ) Research

Nunzia Pharmaceutical Company operates within the pharmaceutical and nutraceutical sectors. The firm possesses the exclusive rights to produce, promote, and distribute Nunzia, a key nutraceutical product specifically designed to address conditions like autism, fragile X syndrome, ADHD, PTSD, and various other disorders. Its offerings are made available through a network of wholesalers and directly via its official website, nunziapharma.com. Incorporated in 1986, the company, headquartered in Long Beach, California, transitioned to its present name, Nunzia Pharmaceutical Company, in February 2018, having previously been known as Arizona Gold and Onyx Mining Company.

Market snapshot

Symbol
NUNZ
Price
$0.00
Day change
0.00%
Market cap
$43.5K
P/E ratio
-0.00x
52-week range
0.0001-0.003
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • ARYx Therapeutics, Inc. (ARYX)
  • Abattis Bioceuticals Corp. (ATTBF)
  • Instadose Pharma Corp. (INSD)
  • Isodiol International Inc. (ISOLF)
  • Nutranomics, Inc. (NNRX)
  • Onassis Holdings Corp. (ONSS)
  • OWC Pharmaceutical Research Corp. (OWCP)
  • Virtual Medical International, Inc. (QEBR)

Recent insider activity

  • HENRY G DAVID — P-Purchase (25000 shares) on 2006-10-30
  • HENRY G DAVID — P-Purchase (100000 shares) on 2006-10-18
  • HENRY G DAVID — P-Purchase (10000 shares) on 2006-06-14
  • HENRY G DAVID — P-Purchase (3913 shares) on 2006-05-03
  • HENRY G DAVID — P-Purchase (55000 shares) on 2006-05-02

Open Nunzia Pharmaceutical Company (NUNZ) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.